Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma
A phase 1 clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center has found that an investigational CAR-T therapy can lead to deep and durable responses in people with relapsed or refractory multiple myeloma. Results are published in The New England Journal of Medicine.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
COVID-19 pandemic drove violence and moral suffering for nurses in Latin America
-
Chronic pain after cesarean delivery linked to poorer quality of life for months and years after giving birth
-
Risk of death rises with rate of overcrowding, corridor care in hospital emergency department
-
New ambulance triage method could reduce emergency visits for chest pain
-
Violence against emergency workers is increasing: Hospital overcrowding a major contributor
-
AI innovation supports screening for 2.2 million US workers exposed to toxic dust
-
Wiskott-Aldrich syndrome: Long-term results of gene therapy developed
-
Three heart cell receptors share unexpected signal that drives scar formation